Acknowledging that CC-16 and SP-D are suggested as valuable biomarkers for ARDS, the first objective of this investigation is to investigate the behavior of these proteins according to the clinical evolution and severity of COVID-19. This evidence concerns the gene SCGB1A1 and acute respiratory distress syndrome.